Lamassu Pharma: Funding, Investors & Team (Oct 2026)
Lamassu Pharma is a biotech startup addressing a crucial medical problem with severe acute pancreatitis. They have developed a new small molecule therapy for this condition, originally created by top scientists at Mayo Clinic. This treatment has shown promising results in preclinical studies, effectively reducing the mortality and morbidity rates of severe acute pancreatitis. The company is now focused on conducting safety tests in order to move towards clinical trials, with the primary objective of saving the lives of patients suffering from this disease.
Lamassu Pharma has raised $2.1M across 1 funding round on record, the most recent an undisclosed round of $2.1M announced in Mar 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lamassu Pharma Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Lamassu Pharma Funding Rounds
Lamassu Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Lamassu Pharma Funding Compared to Other Biotechnology Startups
Lamassu Pharma's latest round of $2.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lamassu Pharma in Biotechnology and Durham
Companies Similar to Lamassu Pharma
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Lamassu Pharma Funding FAQs
What does Lamassu Pharma do?
Lamassu Pharma is a biotech startup addressing a crucial medical problem with severe acute pancreatitis. They have developed a new small molecule therapy for this condition, originally created by top scientists at Mayo Clinic. This treatment has shown promising results in preclinical studies, effectively reducing the mortality and morbidity rates of severe acute pancreatitis. The company is now focused on conducting safety tests in order to move towards clinical trials, with the primary objective of saving the lives of patients suffering from this disease.
How much funding has Lamassu Pharma raised?
Lamassu Pharma has raised $2.1M across 1 round on record. The most recent is an undisclosed round of $2.1M announced in Mar 2024.
When did Lamassu Pharma last raise funding?
Lamassu Pharma's most recent funding round on record is an undisclosed round of $2.1M, announced in Mar 2024.
Who founded Lamassu Pharma?
FundedIQ lists Gabi Hanna (Founder) at Lamassu Pharma.
Where is Lamassu Pharma headquartered?
Lamassu Pharma is based in Durham, North Carolina, United States.
How many employees does Lamassu Pharma have?
Lamassu Pharma is in the 1-10 employee band.
How does Lamassu Pharma's funding compare to other Biotechnology startups?
Lamassu Pharma's latest round of $2.1M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Lamassu Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lamassu Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.